Cargando…

Prognostic and therapeutic value of disruptor of telomeric silencing-1-like (DOT1L) expression in patients with ovarian cancer

BACKGROUND: Epigenetics has been known to play a critical role in regulating the malignant phenotype. This study was designed to examine the expression of DOT1L (histone 3 lysine 79 methyltransferase) and H3K79 methylation in normal ovarian tissues and ovarian tumors and to explore the function of D...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Xiaoxue, Liu, Dan, Li, Mengchen, Cao, Canhui, Wan, Dongyi, Xi, Bixin, Li, Wenqian, Tan, Jiahong, Wang, Ji, Wu, Zhongcai, Ma, Ding, Gao, Qinglei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5259947/
https://www.ncbi.nlm.nih.gov/pubmed/28114995
http://dx.doi.org/10.1186/s13045-017-0400-8
_version_ 1782499309404553216
author Zhang, Xiaoxue
Liu, Dan
Li, Mengchen
Cao, Canhui
Wan, Dongyi
Xi, Bixin
Li, Wenqian
Tan, Jiahong
Wang, Ji
Wu, Zhongcai
Ma, Ding
Gao, Qinglei
author_facet Zhang, Xiaoxue
Liu, Dan
Li, Mengchen
Cao, Canhui
Wan, Dongyi
Xi, Bixin
Li, Wenqian
Tan, Jiahong
Wang, Ji
Wu, Zhongcai
Ma, Ding
Gao, Qinglei
author_sort Zhang, Xiaoxue
collection PubMed
description BACKGROUND: Epigenetics has been known to play a critical role in regulating the malignant phenotype. This study was designed to examine the expression of DOT1L (histone 3 lysine 79 methyltransferase) and H3K79 methylation in normal ovarian tissues and ovarian tumors and to explore the function of DOT1L and its underline mechanisms in ovarian cancer. METHODS: The expression of DOT1L and H3K79 methylation in 250 ovarian tumor samples and 24 normal ovarian samples was assessed by immunohistochemistry. The effects of DOT1L on cell proliferation in vitro were evaluated using CCK8, colony formation and flow cytometry. The DOT1L-targeted genes were determined using chromatin immune-precipitation coupled with high-throughput sequencing (ChIP-seq) and ChIP-PCR. Gene expression levels were measured by real-time PCR and immunoblotting. The effects of DOT1L on tumor growth in vivo were evaluated using an orthotopic ovarian tumor model. RESULTS: DOT1L expression and H3K79 methylation was significantly increased in malignant ovarian tumors. High DOT1L expression was associated with International Federation of Gynecology and Obstetrics (FIGO) stage, histologic grade, and lymphatic metastasis. DOT1L was an independent prognostic factor for the overall survival (OS) and progression-free survival (PFS) of ovarian cancer, and higher DOT1L expression was associated with poorer OS and PFS. Furthermore, DOT1L regulates the transcription of G1 phase genes CDK6 and CCND3 through H3K79 dimethylation; therefore, blocking DOT1L could result in G1 arrest and thereby impede the cell proliferation in vitro and tumor growth in vivo. CONCLUSIONS: Our findings first demonstrate that DOT1L over-expression has important clinical significance in ovarian cancer and also clarify that it drives cell cycle progression through transcriptional regulation of CDK6 and CCND3 through H3K79 methylation, suggesting that DOT1L might be potential target for prognostic assessment and therapeutic intervention in ovarian cancer. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13045-017-0400-8) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5259947
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-52599472017-01-26 Prognostic and therapeutic value of disruptor of telomeric silencing-1-like (DOT1L) expression in patients with ovarian cancer Zhang, Xiaoxue Liu, Dan Li, Mengchen Cao, Canhui Wan, Dongyi Xi, Bixin Li, Wenqian Tan, Jiahong Wang, Ji Wu, Zhongcai Ma, Ding Gao, Qinglei J Hematol Oncol Research BACKGROUND: Epigenetics has been known to play a critical role in regulating the malignant phenotype. This study was designed to examine the expression of DOT1L (histone 3 lysine 79 methyltransferase) and H3K79 methylation in normal ovarian tissues and ovarian tumors and to explore the function of DOT1L and its underline mechanisms in ovarian cancer. METHODS: The expression of DOT1L and H3K79 methylation in 250 ovarian tumor samples and 24 normal ovarian samples was assessed by immunohistochemistry. The effects of DOT1L on cell proliferation in vitro were evaluated using CCK8, colony formation and flow cytometry. The DOT1L-targeted genes were determined using chromatin immune-precipitation coupled with high-throughput sequencing (ChIP-seq) and ChIP-PCR. Gene expression levels were measured by real-time PCR and immunoblotting. The effects of DOT1L on tumor growth in vivo were evaluated using an orthotopic ovarian tumor model. RESULTS: DOT1L expression and H3K79 methylation was significantly increased in malignant ovarian tumors. High DOT1L expression was associated with International Federation of Gynecology and Obstetrics (FIGO) stage, histologic grade, and lymphatic metastasis. DOT1L was an independent prognostic factor for the overall survival (OS) and progression-free survival (PFS) of ovarian cancer, and higher DOT1L expression was associated with poorer OS and PFS. Furthermore, DOT1L regulates the transcription of G1 phase genes CDK6 and CCND3 through H3K79 dimethylation; therefore, blocking DOT1L could result in G1 arrest and thereby impede the cell proliferation in vitro and tumor growth in vivo. CONCLUSIONS: Our findings first demonstrate that DOT1L over-expression has important clinical significance in ovarian cancer and also clarify that it drives cell cycle progression through transcriptional regulation of CDK6 and CCND3 through H3K79 methylation, suggesting that DOT1L might be potential target for prognostic assessment and therapeutic intervention in ovarian cancer. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13045-017-0400-8) contains supplementary material, which is available to authorized users. BioMed Central 2017-01-23 /pmc/articles/PMC5259947/ /pubmed/28114995 http://dx.doi.org/10.1186/s13045-017-0400-8 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Zhang, Xiaoxue
Liu, Dan
Li, Mengchen
Cao, Canhui
Wan, Dongyi
Xi, Bixin
Li, Wenqian
Tan, Jiahong
Wang, Ji
Wu, Zhongcai
Ma, Ding
Gao, Qinglei
Prognostic and therapeutic value of disruptor of telomeric silencing-1-like (DOT1L) expression in patients with ovarian cancer
title Prognostic and therapeutic value of disruptor of telomeric silencing-1-like (DOT1L) expression in patients with ovarian cancer
title_full Prognostic and therapeutic value of disruptor of telomeric silencing-1-like (DOT1L) expression in patients with ovarian cancer
title_fullStr Prognostic and therapeutic value of disruptor of telomeric silencing-1-like (DOT1L) expression in patients with ovarian cancer
title_full_unstemmed Prognostic and therapeutic value of disruptor of telomeric silencing-1-like (DOT1L) expression in patients with ovarian cancer
title_short Prognostic and therapeutic value of disruptor of telomeric silencing-1-like (DOT1L) expression in patients with ovarian cancer
title_sort prognostic and therapeutic value of disruptor of telomeric silencing-1-like (dot1l) expression in patients with ovarian cancer
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5259947/
https://www.ncbi.nlm.nih.gov/pubmed/28114995
http://dx.doi.org/10.1186/s13045-017-0400-8
work_keys_str_mv AT zhangxiaoxue prognosticandtherapeuticvalueofdisruptoroftelomericsilencing1likedot1lexpressioninpatientswithovariancancer
AT liudan prognosticandtherapeuticvalueofdisruptoroftelomericsilencing1likedot1lexpressioninpatientswithovariancancer
AT limengchen prognosticandtherapeuticvalueofdisruptoroftelomericsilencing1likedot1lexpressioninpatientswithovariancancer
AT caocanhui prognosticandtherapeuticvalueofdisruptoroftelomericsilencing1likedot1lexpressioninpatientswithovariancancer
AT wandongyi prognosticandtherapeuticvalueofdisruptoroftelomericsilencing1likedot1lexpressioninpatientswithovariancancer
AT xibixin prognosticandtherapeuticvalueofdisruptoroftelomericsilencing1likedot1lexpressioninpatientswithovariancancer
AT liwenqian prognosticandtherapeuticvalueofdisruptoroftelomericsilencing1likedot1lexpressioninpatientswithovariancancer
AT tanjiahong prognosticandtherapeuticvalueofdisruptoroftelomericsilencing1likedot1lexpressioninpatientswithovariancancer
AT wangji prognosticandtherapeuticvalueofdisruptoroftelomericsilencing1likedot1lexpressioninpatientswithovariancancer
AT wuzhongcai prognosticandtherapeuticvalueofdisruptoroftelomericsilencing1likedot1lexpressioninpatientswithovariancancer
AT mading prognosticandtherapeuticvalueofdisruptoroftelomericsilencing1likedot1lexpressioninpatientswithovariancancer
AT gaoqinglei prognosticandtherapeuticvalueofdisruptoroftelomericsilencing1likedot1lexpressioninpatientswithovariancancer